ESMO E-Learning: Advances in Gastric Cancer: How to Approach Localised Disease

Learning Objectives

  • To provide an update on clinical assessment, staging work-up and importance of multidisciplinary team discussion in patients with localised gastric cancer
  • To provide an update on current recommendations for treatment sequence in patients with localised gastric cancer
  • To provide an update on currently available medical treatments in patients with localised gastric cancer

After two years E-Learning modules are no longer considered current. There is therefore no CME test associated with this E-Learning module.

Title Duration Content CME Points CME Test
Advances in Gastric Cancer: How to Approach Localised Disease 30 min. 33 slides 1 Take Test
Andres Cervantes
Andrés Cervantes
Read more

This module provides an essential explanation on the shift away from the classical approach to localised gastric cancer that considered surgical resection, pathology assessment and risk estimation, treatment based upon classical TNM staging, postoperative chemotherapy or postoperative chemoradiation to the currently recommended approach with the following steps: clinical assessment and staging, multidisciplinary team discussion, preoperative treatment, surgical resection after chemotherapy, pathology assessment and estimation of risk, postoperative chemotherapy if tolerated. In addition, it advocates for the participation in clinical trials.

Adjuvant chemotherapy failed to show any positive effect after surgery in gastric cancer. Aims of the neoadjuvant therapy are to increase R0 resection rate, to allow early treatment of micrometastasis, to reduce locoregional relapses, and to allow biological studies.

A multidisciplinary approach is needed for localised gastric cancer. Preoperative treatment is preferred as it is better tolerated than postoperative therapy. Quality of surgery is essential and the role of radiotherapy is still experimental. Further research on biological predictive factors is needed.

This module provides the evidence that in operable gastric and lower oesophageal cancer, perioperative chemotherapy leads to downsizing of primary tumour, significantly improves progression-free survival and significantly improves overall survival.

In this module, the author reviews studies and provides algorithms for currently best practices in the management of patients with localised gastric cancer. 

This E-Learning module was published in 2015 and expired in 2017.

Last update: 02 July 2015

The author is a member of the speaker’s bureau for Roche and Merck Serono. He has participated in advisory boards for Merck Serono, Roche, Amgen, Bayer and Lilly.